Company performance
Add to research
Current Price
as of Mar 12, 2025$32.61
P/E Ratio
N/A
Market Cap
$3.92B
Loading...
Description
Add to research
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerRNA
- Price$32.61+10.24%
Trading Information
- Market cap$3.92B
- Float92.39%
- Average Daily Volume (1m)1,254,581
- Average Daily Volume (3m)1,348,369
- EPS-$2.89
Company
- Revenue$10.90M
- Rev growth (1yr)13.99%
- Net income-$322.30M
- Gross margin74.53%
- EBITDA margin-3,451.96%
- EBITDA-$376.16M
- EV$1.75B
- EV/Revenue160.60
- P/EN/A
- P/S333.92
- P/B2.74
- Debt/Equity0.48
Documents
Add to research
SEC Filings
Factset Street Account